Comparative demographics of patients receiving 14 days versus 21 days of tipifarnib
| Characteristic . | 14-day schedule, % (n = 54) . | 21-day schedule, % (n = 30) . | P . |
|---|---|---|---|
| Age > 75 y | 69 | 68 | > .999 |
| No. of comorbidities | .85 | ||
| 0 | 9 | 13 | |
| 1 | 19 | 20 | |
| 2 | 28 | 20 | |
| 3 | 44 | 47 | |
| Adverse cytogenetics | 56 | 47 | .50 |
| Secondary AML | 50 | 60 | .49 |
| Characteristic . | 14-day schedule, % (n = 54) . | 21-day schedule, % (n = 30) . | P . |
|---|---|---|---|
| Age > 75 y | 69 | 68 | > .999 |
| No. of comorbidities | .85 | ||
| 0 | 9 | 13 | |
| 1 | 19 | 20 | |
| 2 | 28 | 20 | |
| 3 | 44 | 47 | |
| Adverse cytogenetics | 56 | 47 | .50 |
| Secondary AML | 50 | 60 | .49 |